stoxline Quote Chart Rank Option Currency Glossary
  
Kamada Ltd. (KMDA)
5.08  0.18 (3.67%)    04-17 16:00
Open: 4.95
High: 5.2638
Volume: 34,477
  
Pre. Close: 4.9
Low: 4.942
Market Cap: 292(M)
Technical analysis
2024-04-17 4:47:50 PM
Short term     
Mid term     
Targets 6-month :  6.48 1-year :  6.94
Resists First :  5.54 Second :  5.94
Pivot price 5.34
Supports First :  4.9 Second :  4.07
MAs MA(5) :  5.08 MA(20) :  5.44
MA(100) :  5.73 MA(250) :  5.3
MACD MACD :  -0.3 Signal :  -0.2
%K %D K(14,3) :  8.3 D(3) :  5.1
RSI RSI(14): 34.4
52-week High :  6.53 Low :  4.07
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ KMDA ] has closed above bottom band by 20.0%. Bollinger Bands are 13.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.28 - 5.31 5.31 - 5.34
Low: 4.86 - 4.9 4.9 - 4.94
Close: 5.01 - 5.08 5.08 - 5.14
Company Description

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Headline News

Mon, 15 Apr 2024
Kamada Ltd. (NASDAQ:KMDA) Sees Large Drop in Short Interest - MarketBeat

Fri, 12 Apr 2024
Kamada (NASDAQ:KMDA) Share Price Crosses Below 200 Day Moving Average of $5.47 - MarketBeat

Wed, 06 Mar 2024
Kamada: Q4 Earnings Snapshot - Quartz

Wed, 06 Mar 2024
Kamada Ltd. (KMDA) Q4 2023 Earnings Call Transcript - Seeking Alpha

Wed, 28 Feb 2024
LLY: Navigate to Success With These 4 Pharma Stocks to Buy - StockNews.com

Fri, 12 Jan 2024
NVS: Will These 3 Pharma Stocks Become Gainers in 2024? - StockNews.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 57 (M)
Shares Float 9 (M)
Held by Insiders 7.3 (%)
Held by Institutions 49.4 (%)
Shares Short 40 (K)
Shares Short P.Month 52 (K)
Stock Financials
EPS 0.15
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.23
Profit Margin 5.8 %
Operating Margin 7.6 %
Return on Assets (ttm) 1.8 %
Return on Equity (ttm) 3.9 %
Qtrly Rev. Growth -19.8 %
Gross Profit (p.s.) 0
Sales Per Share 2.47
EBITDA (p.s.) 0.37
Qtrly Earnings Growth 22.7 %
Operating Cash Flow 4 (M)
Levered Free Cash Flow -17 (M)
Stock Valuations
PE Ratio 33.86
PEG Ratio 3.9
Price to Book value 1.19
Price to Sales 2.04
Price to Cash Flow 67.59
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android